 Antibody biologics have revolutionized medicine due to their superior target specificity, pharmacokinetics and pharmacodynamics, safety and toxicity profiles, and amenability to versatile engineering. The development of large molecule antibodies requires a comprehensive understanding of the underlying mechanisms involved in their generation, production, characterization, and formulation. This review provides an overview of the current state of antibody developability, focusing on the preclinical phase of drug discovery and development. It discusses the importance of developing robust processes and strategies to ensure successful antibody candidates reach the clinic. This article was authored by Carl Mechkowski, Chiwe Jinjong, Dana Lee, and others.